ストックスクリーナーアプリを入手
2.83
5.99%
0.16
アフターアワーズ：
2.83
Moleculin Biotech Inc (MBRX) 最新ニュース
Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World
Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World
What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World
Moleculin Biotech Unveils New Corporate Presentation - TipRanks
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire
Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World
Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com
Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph
Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com
Moleculin Biotech advances Annamycin AML trial protocol - Investing.com
Moleculin Biotech Accelerates Annamycin Phase 3 Trial - TipRanks
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PR Newswire
Maxim Group Has Lowered Expectations for Moleculin Biotech (NASDAQ:MBRX) Stock Price - Defense World
Moleculin Biotech Reports Financial Highlights and Future Plans - Yahoo Finance
Moleculin gets IRB nod for Phase 3 AML trial - Investing.com India
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Moleculin gets IRB nod for Phase 3 AML trial By Investing.com - Investing.com Nigeria
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire
Earnings call: Moleculin Biotech optimistic on Annamycin's trial By Investing.com - Investing.com Australia
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Company Announcement - Financial Times
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Moleculin Biotech Inc. (MBRX) Quarterly 10-Q Report - Quartz
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Moleculin Biotech (MBRX) Set to Announce Quarterly Earnings on Friday - Defense World
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - StreetInsider.com
Moleculin Biotech : to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast Form 8 K - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - Star Local Media
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - GuruFocus.com
Soft Tissue Sarcoma Market Growth to Accelerate in Forecast - openPR
Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World
Moleculin Biotech stockholders approve new stock plan By Investing.com - Investing.com South Africa
Moleculin to Participate in the Virtual Investor Lunch Break: Th - GuruFocus.com
Moleculin Abstract Accepted for Poster Presentation at the Europ - GuruFocus.com
Moleculin Biotech stockholders approve new stock plan - Investing.com India
Moleculin Biotech’s Annual Meeting Decisions and Elections - TipRanks
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential - Yahoo Finance
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - Financial Times
Ependymoma Market to Rise by 2032, DelveInsight | Fera - openPR
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: P - GuruFocus.com
Moleculin Announces Proposed Underwritten Public Offering - Marketscreener.com
Moleculin Announces Full Exercise of Over-Allotment Option - Marketscreener.com
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update - TipRanks
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin to Present at Two Upcoming Investor Conferences - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World
Moleculin to Present at Two Upcoming Investor Conferences – Company Announcement - Financial Times
Moleculin Biotech Releases Updated Corporate Presentation - TipRanks
Moleculin Biotech (NASDAQ:MBRX) Receives New Coverage from Analysts at StockNews.com - Defense World
Moleculin Biotech Shares Rise 12% After Positive Annamycin Data - MarketWatch
Moleculin Biotech Sees Positive Data From Annamycin Study - MarketWatch
Moleculin Biotech’s Annamycin Shows Promise in Cancer Treatment - TipRanks
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):